Navigation Links
This week in Blood: Jan. 10, 2013
Date:1/10/2013

Welcome to "This Week in Blood," a weekly snapshot of the hottest studies from each week's issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Lwenberg, MD, and Deputy Editor Nancy Berliner, MD.

Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma, Dovedi et al.

This week's plenary paper offers a promising potential new immunotherapeutic modality for the treatment of lymphoma. The authors present convincing data to suggest that a toll-like receptor 7 (TLR7) agonist sensitizes tumor cells to radiotherapy. In a mouse model, this increases radiation-induced cell death and prolongs responses.

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia, Horn et al.

The success of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML) has led to early investigation of the safety of discontinuing therapy for patients with prolonged deep response to treatment. In this manuscript, Horn and colleagues present a way of predicting the safety of therapy discontinuation.

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms, Cazzola et al.

This manuscript, featured as this week's Perspective, discusses how our understanding of the pathophysiology of myelodysplastic syndromes (MDS) and other hematologic malignancies has been transformed over the last year with the discovery of the prevalence and prognostic significance of mutations in genes encoding the cellular splicing machinery.


'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Patient Survival Rises When Drugs Suppress Hepatitis C in Blood: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology: